MX2022009309A - Compuestos y usos de los mismos. - Google Patents

Compuestos y usos de los mismos.

Info

Publication number
MX2022009309A
MX2022009309A MX2022009309A MX2022009309A MX2022009309A MX 2022009309 A MX2022009309 A MX 2022009309A MX 2022009309 A MX2022009309 A MX 2022009309A MX 2022009309 A MX2022009309 A MX 2022009309A MX 2022009309 A MX2022009309 A MX 2022009309A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
present disclosure
related disorders
compounds useful
Prior art date
Application number
MX2022009309A
Other languages
English (en)
Inventor
Rishi G Vaswani
David S Huang
Original Assignee
Foghorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foghorn Therapeutics Inc filed Critical Foghorn Therapeutics Inc
Publication of MX2022009309A publication Critical patent/MX2022009309A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

La presente descripción presenta compuestos útiles para el tratamiento de trastornos relacionados con el complejo BAF.
MX2022009309A 2020-01-29 2021-01-29 Compuestos y usos de los mismos. MX2022009309A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967359P 2020-01-29 2020-01-29
PCT/US2021/015876 WO2021155262A1 (en) 2020-01-29 2021-01-29 Compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2022009309A true MX2022009309A (es) 2022-08-22

Family

ID=76970694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009309A MX2022009309A (es) 2020-01-29 2021-01-29 Compuestos y usos de los mismos.

Country Status (15)

Country Link
US (3) US11485732B2 (es)
EP (1) EP4096664A4 (es)
JP (1) JP2023512039A (es)
KR (1) KR20220133258A (es)
CN (1) CN115023226A (es)
AR (1) AR121226A1 (es)
AU (1) AU2021213811A1 (es)
BR (1) BR112022015004A2 (es)
CA (1) CA3167275A1 (es)
CO (1) CO2022010547A2 (es)
IL (1) IL295100A (es)
MX (1) MX2022009309A (es)
TW (1) TW202136252A (es)
WO (1) WO2021155262A1 (es)
ZA (1) ZA202207804B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4304600A1 (en) * 2021-03-09 2024-01-17 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2022198043A1 (en) * 2021-03-19 2022-09-22 Foghorn Therapeutics Inc. Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm
WO2023009834A2 (en) * 2021-07-29 2023-02-02 Foghorn Therapeutics Inc. Methods of treating cancer
WO2023196565A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics, Inc. Methods of treating cancer
WO2023196560A1 (en) * 2022-04-08 2023-10-12 Foghorn Therapeutics Inc. Methods of treating cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2788341A (en) 1953-03-06 1957-04-09 Ciba Pharm Prod Inc Process for the manufacture of aminoacyl compounds
US3624097A (en) 1969-07-22 1971-11-30 Warner Lambert Co N-pyridine 5-aminooxazoles
US20050079512A1 (en) 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
US8518960B2 (en) 2007-05-23 2013-08-27 Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection
MY192693A (en) 2010-03-17 2022-09-01 Taivex Therapeutics Inc Modulators of hec1 activity and methods therefor
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
EP2971094B1 (en) 2013-03-15 2021-09-15 Novartis AG Biomarkers associated with brm inhibition
AU2014237198A1 (en) 2013-03-15 2015-11-05 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
US10976320B2 (en) 2013-05-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for identifying and treating cancer patients
WO2015005473A1 (ja) 2013-07-12 2015-01-15 独立行政法人国立がん研究センター がんの治療への応答性を予測する方法
JPWO2015046193A1 (ja) * 2013-09-25 2017-03-09 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
EP3102193B1 (en) 2014-02-06 2023-01-11 Rutgers, The State University of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
JP6315150B2 (ja) 2016-02-29 2018-04-25 フジテック株式会社 情報提供装置、エレベータの群管理システム、及びエレベータシステム
SG10202109335TA (en) * 2017-02-28 2021-10-28 Epizyme Inc Inhibition of smarca2 for treatment of cancer
US20200206344A1 (en) 2017-08-21 2020-07-02 Dana-Farber Cancer Institute, Inc. Methods for modulating the interaction between ews-fli1 and baf complexes
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3801494A4 (en) 2018-05-25 2022-05-11 Rutgers, The State University of New Jersey ANTIBACTERIAL AGENTS: DUAL TARGETING RNA POLYMERASE INHIBITORS
LT3837256T (lt) 2018-08-17 2023-06-12 Novartis Ag Karbamido junginiai ir kompozicijos kaip smarca2 / brm atfazės inhibitoriai
US20210388040A1 (en) 2018-10-17 2021-12-16 Dana-Farber Cancer Institute, Inc. Non-canonical swi/snf complex and uses thereof
US20230035235A1 (en) 2018-10-17 2023-02-02 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
WO2020106915A1 (en) * 2018-11-21 2020-05-28 Foghorn Therapeutics Inc. Methods of treating cancers
WO2020160180A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160100A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021081032A1 (en) 2019-10-25 2021-04-29 Dana-Farber Cancer Institute, Inc. Compositions comprising modified smarcb1 and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021183218A1 (en) 2020-03-13 2021-09-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes

Also Published As

Publication number Publication date
JP2023512039A (ja) 2023-03-23
WO2021155262A1 (en) 2021-08-05
AR121226A1 (es) 2022-04-27
CN115023226A (zh) 2022-09-06
US11485732B2 (en) 2022-11-01
EP4096664A1 (en) 2022-12-07
TW202136252A (zh) 2021-10-01
KR20220133258A (ko) 2022-10-04
IL295100A (en) 2022-09-01
US20210230154A1 (en) 2021-07-29
BR112022015004A2 (pt) 2022-09-20
CO2022010547A2 (es) 2022-09-09
CA3167275A1 (en) 2021-08-05
AU2021213811A1 (en) 2022-07-28
EP4096664A4 (en) 2024-02-28
US20230129003A1 (en) 2023-04-27
ZA202207804B (en) 2023-12-20
US20240101550A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
MX2022012474A (es) Compuestos y usos de estos.
ZA202207804B (en) Compounds and uses thereof
MX2022009369A (es) Compuestos y usos de estos.
MX2022009308A (es) Compuestos y usos de estos.
AU2021213258B2 (en) Compounds and uses thereof
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
WO2022109396A8 (en) Compounds and uses thereof
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
EP4295846A3 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2021013661A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
WO2021022163A3 (en) Compounds and uses thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
GEP20227443B (en) Magl inhibitors
MX2023005436A (es) Compuestos y usos de estos.
EP4316592A3 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2022009367A (es) Compuestos y usos de estos.
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.